Driven by new advances in laboratory techniques, researchers are peering ever more closely at the oocyte as it develops from its meiotically quiescent state to the germinal vesicle stage, where it is poised for ovulation.
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As the oocyte develops, its nearly naked DNA acquires a heavy load of methyl modifications. This process has long been thought to involve methylation at the cytosine CG sites almost exclusively, but recent studies have shown that non-CG methylation also occurs.
Kenjiro Shirane et al. have leveraged advances in ''Methylome'' analysis to take a close look at non-CG methylation. They first assessed the prevalence of non-CG methylation as oocytes grew, and then pieced together which enzymes were responsible for the modification.
The researchers deployed a modified form of whole-genome bisulfite sequencing, which is a technique for globally assessing methylation that works on nanogram quantities of DNA. In nongrowing oocytes taken from neonatal mice at the time of follicle formation, methylation at CG sites was low, at about 2.3%. Methylation levels increased to about 38% in germinal vesicle oocytes, consistent with previous results.
The researchers similarly observed a large increase in methylation at non-CG sites, increasing from apparently no methylation in the nongrowing state to a high proportion at the germinal vesicle stage: about 66% of methylation occurred at non-CG sites. The methylation of CG and non-CG sites seemed to occur in a coordinated fashion in the same genomic regions. Moreover, the process required the same regulators, the methyltransferase Dnmt3a and its accessory protein Dnmt3L.
Methylation on non-CG nucleotides occurs de novo, and, unlike CG methylation, is not re-established during cell division. The researchers point out that this may explain why such methylation has also been observed in other non-dividing and slowly dividing cells, such as brain cells and certain pluripotent stem cells. The findings provide a strong basis for future experiments uncovering the biological role of this form of methylation. Germ cells proliferate during embryonic development to create the cells that ultimately give rise to sperm and eggs. In many species, this process includes a stage in which germ cells are connected to each other through cytoplasmic bridges, followed by apoptosis of some of the cells. Researchers have now examined this process in mice and found that it may promote optimal germline selection.
Lei Lei and Allan Spradling developed a labeling method that enabled them to activate a fluorescent label, YFP, in embryonic primordial germ cells prior to their mitotic proliferation. The label was activated in only about one primordial germ cell per mouse, enabling the researchers to track the fate of an individual germ cell.
As shown in Figure 1 , the researchers found that each primordial germ cell gives rise to a cyst of synchronously dividing, interconnected cells. These cysts typically reach about 30 cells in number before mitotic division ceases, but by then the cysts have begun to fragment, losing some of their cellular connections. As they do so, the fragments associate with fragments from other cysts, although germ cells in the resulting nests of cells are interconnected and synchronized within the original fragment only.
In females, cyst fragmentation and aggregation occurs before and during meiosis I. In both sexes, the nests of cells eventually break apart and, by birth, the germ cells are isolated. The researchers found that apoptosis is uncommon in males, but in females almost 80 percent of these germ cells undergo apoptosis, which is consistent with previous studies. Each primordial germ cell gives rise, on average, to about six primordial follicles in females.
The connections that germ cells form with each other may aid in the transport of organelles and molecules, thereby assuring that the best germ cell from each cyst fragment survives. For instance, mitochondria and other vital materials may be transported to the surviving germ cell, while damaged molecular goods are offloaded to adjacent cells.
This idea has gained considerable experimental support in flies and there is evidence for a similar effect in mammals; for instance, structures called Balbiani bodies form in developing oocytes from cellular contents exchanged over intracellular bridges. The study may provide a model for the process of early gametogenesis in other mammals. Lei A protein transiently expressed on developing sperm is required for proper migration of sperm in the oviduct and it may be a potential target for a male contraceptive.
Yoshitaka Fujihara et al. took a close look at TEX101 (encoded by testis-expressed gene 101), a protein anchored to the cell surface by a GPI-linkage found previously in developing sperm. The researchers noted that TEX101 was expressed abundantly in testicular germ cells through the spermatid stage, but had mostly disappeared in sperm found in the epididymis.
The team next created mice deficient for TEX101 and found that the males were infertile due to a failure of the sperm to migrate into the oviduct. This phenotype resembles that of mice deficient in ADAM3 (a disintegrin and metallopeptidase domain 3), a protein present on mature sperm.
The researchers found that TEX101 associated with ADAM3 and appeared to stabilize it from degradation during sperm maturation. In mice deficient in TEX101, for instance, ADAM3 was processed normally during earlier stages of sperm maturation, but was subsequently degraded.
The role of TEX101 in assisting ADAM3 is a fleeting one. The researchers found that the disappearance of TEX101 during later stages of sperm development was mediated by ACE (angiotensin converting enzyme), which has a well-known role in regulating blood pressure using its peptidase activity. Controversial studies have also implicated the enzyme in processing testicular proteins via removal of GPI linkages.
The new findings hint that TEX101 may be a specific substrate for the GPI-ase activity of ACE. A new approach to maintaining fertility during chemotherapy has emerged following a study in mice. The study outlines how the commonly used chemotherapeutic agent cyclophosphamide damages the ovaries and shows that an investigational new drug can counteract this damage and so maintain fertility [1] .
Chemotherapy can directly hit the ovaries, often causing atrophy, shrinkage, and a reduction in the ovarian reserve (the number of oocytes in a dormant state). The mechanisms behind such effects are poorly understood.
Lital Kalich-Philosoph, Hadassa Roness, and colleagues took a close look at the ovaries of mice treated with cyclophosphamide, which is commonly used to treat breast, ovarian, and other cancers. The researchers found that cyclophosphamide attacks the ovaries by a twofold mechanism: it is toxic to dividing cells and kills actively growing ovarian follicles, and, at the same time, it also activates the dormant follicles, inducing them to grow and proliferate, which makes them susceptible to the effects of the drug as well. In this way, cyclophosphamide treatment depletes the ovarian reserve, leading to early ovarian failure and infertility.
The researchers observed that cyclophosphamide activated dormant follicles by turning on the PI3K/PTEN/Akt pathway, which is known to prompt maturation of primordial follicles. The researchers also found that the investigational drug AS101 could counteract the effects of cyclophosphamide, restoring fertility when co-administered to mice with the chemotherapy agent. AS101 has several biochemical effects on cells and is known to counteract the PI3K/PTEN/Akt pathway, an activity that may explain its effect in these experiments.
AS101 is in phase II clinical studies investigating whether it can help alleviate chemotherapy-induced damage to blood and skin; the drug does not seem to dampen the beneficial impact of chemotherapy on tumors.
It is becoming clear that selective modification of signaling pathways can maintain the competence of gametes and preserve fertility. For instance, a study from the same groups [2] showed that AS101 can partially protect male mice from reproductive damage induced by cyclophosphamide. And a study last year [3] showed how interfering with the activity of two factors involved in apoptosis may also preserve fertility during cancer treatment. Mild painkillers affect the adult human testis's production of hormones, a study of prostate cancer patients' testicular tissue suggests.
Mild Painkillers May Tweak the Testes
Previous studies in animals and humans have hinted that antiinflammatory medications affect male hormonal systems. To test the effects of such drugs in men, Océane Albert et al. conducted an in vitro assay using whole testes obtained from elderly men with prostate cancer who were not undergoing hormone therapy and were producing spermatozoa.
The researchers fragmented the tissue into explants about the size of a small peppercorn (3 mm 3 ) and exposed them to media containing paracetamol (acetaminophen), acetylsalicylic acid (aspirin), and the prescription medication indomethacin in concentrations found in human serum at normal dosages. The researchers also examined the effects of drugs on a steroid-producing cell line that had previously been used to study anti-androgenic compounds.
All three drugs reduced the production of testosterone in the cell line; however, in the explants, the effects depended on the drug. For instance, all three drugs affected the production of testosterone in explants after 24 hours of exposure, compared with control explants exposed to culture medium without the drugs. But the effect was only significant (P , 0.05) for paracetamol and indomethacin. Only indomethacin and aspirin affected levels of another hormone, insulinlike 3 (INSL3). Aspirin quelled the production of inhibin-B by 11 percent, while the other drugs had no effect on the production of this hormone. After 48 hours, most of the effects of the drugs were not present, possibly because the drugs had been metabolized.
The mechanism behind the effects of these drugs on the testes is unclear. Aspirin and indomethacin inhibit both isoforms of prostaglandin H2 synthase, the enzymes that synthesize prostaglandins, which are key inflammatory mediators. Paracetamol operates through an unknown mechanism but may also affect the activity of these enzymes, among other effects. In this study, prostaglandin activity seemed to be uncoupled from the effects of the drugs on hormone production; for instance, aspirin and indomethacin quelled prostaglandin activity, but only paracetamol and indomethacin significantly inhibited testosterone production.
This study adds weight to previous research suggesting that mild analgesics may have endocrine-disrupting properties. Epidemiological studies, for instance, have hinted that consumption of paracetamol alone or with other pain relievers during pregnancy may increase the risk of cryptorchidism (undescended testes) in newborn boys. Moreover, some animal studies have suggested that mild analgesics have anti-androgenic effects. For instance, a study in rats showed that paracetamol reduced the anogenital distance of offspring; similarly, paracetamol and aspirin reduced testosterone production in cultured rat fetal testes.
The data on adult men are not clear cut. For instance, healthy young men treated with a normal dose of indomethacin for 14 days had unchanged testosterone levels, as well as unchanged levels of LH and FSH (two other hormones involved in reproduction). But in a separate study, men with low sperm count were found to be susceptible to indomethacin: treatment with the drug for 30 to 90 days resulted in increased plasma FSH and LH concentrations and, paradoxically, decreased plasma testosterone.
The current study suggests that more research is needed to assess the effects of mild analgesics on reproductive function. More data are also needed to determine which prostaglandins are inhibited by analgesics, where in the testis those prostaglandins occur, and what their relationship is to steroid production. 
